132 related articles for article (PubMed ID: 31102765)
1. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract][Full Text] [Related]
2.
Diril M; Özdokur KV; Yıldırım Y; Karasulu HY
Pharm Dev Technol; 2023 Dec; 28(10):915-927. PubMed ID: 37921920
[TBL] [Abstract][Full Text] [Related]
3. Development of Liposomal Gemcitabine with High Drug Loading Capacity.
Tamam H; Park J; Gadalla HH; Masters AR; Abdel-Aleem JA; Abdelrahman SI; Abdelrahman AA; Lyle LT; Yeo Y
Mol Pharm; 2019 Jul; 16(7):2858-2871. PubMed ID: 31136710
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Multidrug Resistance with Transferrin-Targeted Polymersomes through Optimization of Ligand Density.
Yi SL; Li ZL; Gong YC; Xiong XY
Langmuir; 2023 Nov; 39(45):15920-15931. PubMed ID: 37922445
[TBL] [Abstract][Full Text] [Related]
5. Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α.
Zhao R; Cheng S; Bai X; Zhang D; Fang H; Che W; Zhang W; Zhou Y; Duan W; Liang Q; Xiao L; Nie G; Hou Y
Biotechnol J; 2024 Apr; 19(4):e2400050. PubMed ID: 38651271
[TBL] [Abstract][Full Text] [Related]
6. Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin.
Teran-Saavedra NG; Sarabia-Sainz JA; Velázquez-Contreras EF; Ramos-Clamont Montfort G; Pedroza-Montero M; Vazquez-Moreno L
Molecules; 2020 Nov; 25(22):. PubMed ID: 33233564
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma.
Wi TI; Won JE; Lee CM; Lee JW; Kang TH; Shin BC; Han HD; Park YM
Int J Nanomedicine; 2020; 15():8427-8436. PubMed ID: 33149585
[TBL] [Abstract][Full Text] [Related]
8. A fully biodegradable spherical nucleic acid nanoplatform for self-codelivery of doxorubicin and miR122 for innate and adaptive immunity activation.
Jiang MC; Fang ZL; Zhang JY; Ma W; Liao LF; Yu CY; Wei H
Acta Biomater; 2024 May; 180():407-422. PubMed ID: 38614414
[TBL] [Abstract][Full Text] [Related]
9. Long-circulating doxorubicin and Schizandrin A liposome with drug-resistant liver cancer activity:
Xu SY; Wang WW; Qu ZH; Zhang XK; Chen M; Zhang XY; Xing NN; Su H; Wang XY; Cui MY; Yan XY; Ma W
J Liposome Res; 2023 Dec; 33(4):338-352. PubMed ID: 36974767
[TBL] [Abstract][Full Text] [Related]
10. Cancer Cell-Membrane Biomimetic Boron Nitride Nanospheres for Targeted Cancer Therapy.
Feng S; Ren Y; Li H; Tang Y; Yan J; Shen Z; Zhang H; Chen F
Int J Nanomedicine; 2021; 16():2123-2136. PubMed ID: 33731994
[TBL] [Abstract][Full Text] [Related]
11. α
Zou Y; Sun Y; Guo B; Wei Y; Xia Y; Huangfu Z; Meng F; van Hest JCM; Yuan J; Zhong Z
ACS Appl Mater Interfaces; 2020 Apr; 12(13):14905-14913. PubMed ID: 32148016
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional nanotherapeutics for intracellular trafficking of doxorubicin against breast cancer.
Kurmi BD; Patel P; Paliwal R; Kumar P; Paliwal SR
Nanomedicine (Lond); 2023 Aug; 18(19):1261-1279. PubMed ID: 37721134
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats.
Golla K; Cherukuvada B; Ahmed F; Kondapi AK
PLoS One; 2012; 7(12):e51960. PubMed ID: 23284832
[TBL] [Abstract][Full Text] [Related]
14. Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma.
Chen Y; Zhang Y; Wang J; Cai X; Chen J; Min X; Xu Y; Qin Q; Wan C
Int J Nanomedicine; 2024; 19():2227-2239. PubMed ID: 38465206
[TBL] [Abstract][Full Text] [Related]
15. Protein liposomes-mediated targeted acetylcholinesterase gene delivery for effective liver cancer therapy.
Wang K; Shang F; Chen D; Cao T; Wang X; Jiao J; He S; Liang X
J Nanobiotechnology; 2021 Jan; 19(1):31. PubMed ID: 33482834
[TBL] [Abstract][Full Text] [Related]
16. Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma.
Viale M; Bertone V; Maric I; Cilli M; Emionite L; Bocchini V; Ponzoni M; Fontana V; De Luca F; Rocco M
Pharmacol Res; 2021 Jan; 163():105294. PubMed ID: 33217536
[TBL] [Abstract][Full Text] [Related]
17. New Transferrin Receptor-Targeted Peptide-Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity.
Yu J; Mao X; Yang X; Zhao G; Li S
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675578
[TBL] [Abstract][Full Text] [Related]
18. Ameliorative anticancer effect of dendrimeric peptide modified liposomes of letrozole: In vitro and in vivo performance evaluations.
Hegde AR; Paul M; Kumbham S; Roy AA; Ahmad SF; Parekh H; Biswas S; Mutalik S
Int J Pharm; 2023 Dec; 648():123582. PubMed ID: 37940082
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-transferrin conjugate alters mitochondrial homeostasis and energy metabolism in human breast cancer cells.
Wigner P; Zielinski K; Labieniec-Watala M; Marczak A; Szwed M
Sci Rep; 2021 Feb; 11(1):4544. PubMed ID: 33633284
[TBL] [Abstract][Full Text] [Related]
20. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin.
Yousefpour P; Ahn L; Tewksbury J; Saha S; Costa SA; Bellucci JJ; Li X; Chilkoti A
Small; 2019 Mar; 15(12):e1804452. PubMed ID: 30756483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
